News

Asgard Therapeutics becomes a SmiLe member

November 17, 2020

Asgard Therapeutics AB has been admitted to SmiLe Incubator as the next step to move forward on the pre-clinical studies of their lead program TrojanDC. https://news.smileincubator.com/posts/pressreleases/immunotherapy-company-asgard-therapeutics-is

Asgard featured on the Pharma Industry report about ATMPs in Sweden

September 24, 2020

Advanced Therapies Medical Products (ATMPs) are considered the “drugs of the future”. These are based on gene, cell and tissue products. Sweden has the ambitious goal of becoming a leader

Filipe Pereira, Cristiana Pires and Fábio Rosa, co-founders of Asgard Therapeutics, awarded with the Lund University and Sparbanken Skåne’s prize for future innovations

September 23, 2020

Together with Sparbanken Skåne, in collaboration with the Sparbanksstiftelsen Finn, Lund University awarded Filipe Pereira, Cristiana Pires and Fábio Rosa the Lund University and Sparbanken Skåne’s prize for future innovations.

Filipe Pereira, co-founder of Asgard Therapeutics, awarded with a BII PreSeed grant

April 1, 2020

The BioInnovation Institute (BII) awarded Filipe Pereira, co-founder of Asgard Therapeutics, with DKK 3.5M to advance pre-clinical development of dendritic cell reprogramming and define its regulatory roadmap towards the clinic.

Asgard Therapeutics awarded Vinnova’s Innovative Startup Step 2

March 31, 2020

Swedish start-up company Asgard Therapeutics has been awarded the second step of Vinnova’s Innovative Startup program in order to further develop a new cancer immunotherapy based on dendritic cell reprogramming.

Asgard Therapeutics awarded with Lund University Innovation VFT+ Funds

March 29, 2020

Asgard was selected to receive Vinnova’s VFT+ funds managed by LU Innovation for verification activities of TrojanDC towards partners, customers and investors.

Fábio Rosa, co-founder of Asgard Therapeutics, selected for Forbes 30 under 30 List – Europe – Science & Healthcare 2020

March 17, 2020

Fábio Rosa, co-founder of Asgard Therapeutics, was selected by Forbes among 30 brightest young entrepreneurs, innovators and game changers in Science and Healthcare segment. https://www.forbes.com/profile/fabio-rosa/#7376307670f8

Filipe Pereira, co-founder of Asgard Therapeutics, awarded with European Research Council (ERC) Consolidator Grant

December 10, 2019

The European Research Council (ERC) awarded Filipe Pereira, co-founder of Asgard Therapeutics, with an ERC Consolidator Grant to harness dendritic cell reprogramming towards the development of new patient-specific strategies for

Asgard Therapeutics wins NOME entrepreneurship competition

November 29, 2019

Asgard Therapeutics won the Nordic Mentor Network for Entrepreneurship (NOME) Nordic entrepreneurship competition for promising life science companies and becomes part of the Novo Nordisk-funded NOME mentoring network.

Asgard Therapeutics awarded H2020 SMEi phase 1

November 25, 2019

Swedish start-up company Asgard Therapeutics has been awarded H2020 SMEi phase 1 in order to further develop a direct cell reprogramming technology for cancer immunotherapy. Asgard Therapeutics was founded in

Cristiana Pires, CEO and co-founder of Asgard Therapeutics, receives Audience choice Award at BIOEurope Start-up Slam

November 13, 2019

Cristiana Pires, CEO and co-founder of Asgard Therapeutics, awarded with ‘Audience Choice’ Award at BIOEurope Start-up Slam pitch competition promoted by J&J Innovation – JLabs. https://www.ebdgroup.com/bio-europe-2019s-startup-slam-winner-eisbach-bio/

Asgard Therapeutics wins Sten K Johnson Grant

June 30, 2019

Asgard Therapeutics won the Sten K Johnson Grant in the category of Medicine for projects with innovative ideas of medical importance that challenge traditional methods and concepts.